Common Hereditary Cancer Screening Panel
Use
This test is intended for individuals with relevant features suggesting hereditary cancer syndromes, such as those with a clinical or suspected diagnosis of hereditary cancer syndromes, early-onset cancer diagnosis before age 50, a strong family history of cancer, or individuals of Ashkenazi Jewish descent with a personal or family history of relevant cancers. It is valuable for identifying genetic predispositions to cancer and aiding in personalized risk assessments and management plans.
Special Instructions
This test is developed and validated by PreventionGenetics LLC, following CAP and CLIA regulations. Tests have not been cleared or approved by the US FDA. It is available for New York residents as indicated by New York state approvals and requires compliance with state-specific requisition form requirements.
Limitations
The test is based on NGS technology with CNV analysis and may not detect all genetic variations related to hereditary cancer syndromes. False negatives may occur due to limitations in sequence coverage, and variants of unknown significance may be identified without clear clinical interpretation.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided